Clinical Trial Update: Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant and adjuvant imatinib mesylate for primary or recurrent malignant gastrointestinal stromal tumor (GIST) has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED | Results posted: 2013-07-10